Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817840 · ClinicalTrials.gov registry record
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
A clinical trial of Cushing's Syndrome, sponsored by Columbia University.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT03817840 is a study of Cushing's Syndrome that has completed, run by Columbia University. The registered enrollment target is 8 participants, below the 938-participant average among 4 other Cushing's Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03817840, a study of Cushing's Syndrome, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.
Conditions Studied
Interventions
- PROCEDURE Treatment of Cushing's
Study Locations (1)
New York
- Columbia University Neuroendocrine Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2021-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817840
The ClinicalTrials.gov registry entry for NCT03817840 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 938-participant average among 4 other Cushing's Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Treatment of Cushing's is the first listed.
NCT03817840 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03817840 about?
NCT03817840 is a clinical study titled "Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease". This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and...
What is the current status of trial NCT03817840?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2018-07-16. Estimated completion is 2021-07-01.
What conditions does trial NCT03817840 study?
This clinical trial studies the following conditions: Cushing's Syndrome.
What interventions are being tested in trial NCT03817840?
The interventions under investigation include: Treatment of Cushing's (PROCEDURE).
Who is sponsoring clinical trial NCT03817840?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817840 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
RECRUITING · Phase 2
-
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
COMPLETED
-
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
COMPLETED · Phase 2
-
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.